Anti-Human HER-2 (Trastuzumab) – Dylight® 488
Pricing & Details
FC Effector Activity
Human epidermoid carcinoma cells (A431) over-expressing EGFR.
This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze.
Research Use Only (RUO). Non-Therapeutic.
Country of Origin
Next Day 2-8°C
Blue Laser (493 nm)
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for Trastuzumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Other Applications Reported In Literature ?
Additional Reported Applications For Relevant Conjugates ?
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Trastuzumab. Clone 4D5-8 recognizes human erbB-2. This product is for research use only.
Ubiquitous expression with highest expression levels found in the kidney, skin, esophagus, and small intestine.
Trastuzumab is a monoclonal antibody targeting HER2, a 185 kDa transmembrane glycoprotein that contains an extracellular domain and intracellular tyrosine kinase activity. When it is functioning normally, the HER2 pathway supports cell growth and division. On the other hand, the over expression of HER2 propels cell growth beyond its typical range. This overexpression is associated with some cancers, namely breast and stomach, in which the HER2 protein can be expressed up to 100 times more than in typical cells. Trastuzumab induces an immune-mediated response that triggers the internalization and downregulation of HER2 making it an excellent target for immunotherapy. Several clinical studies are under way which show that anti-HER-2/neu antibodies inhibit the growth and proliferation of these tumor cells In vitro as well as In vivo.
NCBI Gene Bank ID
References & Citations
1. Fendly, B. et al. (1990) Cancer Research 50: 1550-1558.
2. McBride, H. et al. (2019) Pharm Res. 36(12): 177.
3. Zielinski, C. et al. (1997) Int. J. Cancer 73: 875–879
4. Valone, FH. et al. (1995) J. Clin. Oncology 13 (9): 2281-92.
5. Hynes, NE. et al. (1993) Br J Cancer. 68(6): 1140–1145.
Products are for research use only. Not for use in diagnostic or therapeutic procedures.